Taplitumomab paptox
Taplitumomab paptox is a monoclonal antibody that was developed for the treatment of cancer. It is also known by its developmental code name, B43.13.
History[edit | edit source]
Taplitumomab paptox was developed by the Immunogen Inc., a biotechnology company specializing in antibody-drug conjugates for the treatment of cancer. The drug was designed to target the CD22 antigen, a protein found on the surface of B cells, which are often involved in certain types of lymphoma and leukemia.
Mechanism of Action[edit | edit source]
Taplitumomab paptox is a monoclonal antibody conjugated to a toxin, hence the "paptox" in its name. The antibody portion of the drug binds to the CD22 antigen on the surface of B cells. Once bound, the drug is internalized by the cell, where the toxin is released. The toxin then interferes with protein synthesis, leading to cell death.
Clinical Trials[edit | edit source]
Taplitumomab paptox underwent Phase I and II clinical trials for the treatment of non-Hodgkin's lymphoma and B-cell acute lymphoblastic leukemia. However, the drug did not progress to Phase III trials, and its development was discontinued.
See Also[edit | edit source]
- Monoclonal antibodies
- Antibody-drug conjugate
- CD22
- Non-Hodgkin's lymphoma
- B-cell acute lymphoblastic leukemia
References[edit | edit source]
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD